Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC
A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.
Read More
Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma
Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC
Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC